Targeting Plasma Cells in Myasthenia Gravis: Translating Clinical Experience Across Autoimmune Diseases

• The evolving treatment landscape in gMG
• Why consider plasma cell targeting Felzartamab: Investigational Anti-CD38 Monoclonal Antibody 
• What clinical experience across autoimmune diseases has taught us: a Phase 2 study on Felzartamab in Antibody Mediated Rejection 
• How these lessons inform future development in gMG

Speakers:

Beatrix Bartok

Vice President - Clinical Development

Biogen